AMLAK

We are asked to produce a JSON output with specific keys: citations, point, risk, stance, confidence, target. The stance must be BUY, HOLD, or SELL based on the RISK lens criteria. We must score concrete breaks only when the cited figure crosses the given thresholds: - ocf_to_ni < 0.7 (accrual-heavy earnings) - net_debt_to_ebitda > 4 - ebitda_interest_cover < 2 - liquidity.advv_30d_aed_m < 1 (exit risk) - quarterly_gaps present (unverifiable trend) - dividend cut evident in financial_statements 0 breaks -> BUY; 1 break -> HOLD unless offset; 2+ cited breaks -> SELL. Never assign SELL without naming which thresholds tripped, with the cited figures. Today is 2026-07-20, horizon ends 2026-08-17 (4 weeks). We must use only the evidence pack. Let's check each threshold: 1. ocf_to_ni: from financial_statements.derived.ocf_to_ni = 1.89. This is >0.7, so not a break. 2. net_debt_to_ebitda: We need to compute net debt and EBITDA. The pack doesn't directly give EBITDA or net debt. But we have annual financials. For 2025: total_debt? Not listed for 2025. In annual list: period "2025-12-31" doesn't have total_debt. But "2024-12-31" has total_debt: 160.3, and "2023-12-31" total_debt: 201.3, "2022-12-31" total_debt: 166.2, "2021-12-31" total_debt: 273.1. For 2025, we don't see total_debt. fundamentals.debt_to_equity = 0.0. So debt is likely zero or negligible. The company may have paid off debt. news from 2025-07-24: "Amlak Finance announces early, full settlement of outstanding financing facilities". So net debt is negative? cash as of 2025-12-31: 2848.7, no debt, so net debt = -cash. EBITDA not given directly, but we can approximate. Operating margin = 69.7269%, revenue 2025 = 2993.9, so operating income ≈ 2993.9 * 0.697269 ≈ 2087. But that's operating income, not EBITDA. Since D&A not given, EBITDA likely higher. Even if low EBITDA, net debt is negative, so ratio <0, definitely not >4. So no break. 3. ebitda_interest_cover: Need EBITDA and interest expense. Not directly given, but debt is zero, so interest expense likely zero or minimal. So coverage very high, no break. 4. liquidity.advv_30d_aed_m: given as 3.0638. This is >1, so no break. 5. quarterly_gaps: We need to check if there are missing quarters in the quarterly data. The quarterly list: periods: "2026-03-31", "2025-12-31", "2025-09-30", "2025-06-30", "2025-03-31", "2024-12-31". That's consecutive. No gaps in the dates provided. However, note that "2024-12-31" is listed but no data? Actually it's there but without figures. Look: the list: {"period": "2024-12-31"} — it has no revenue, net_income, etc. That might be a gap? The presence of a period with no data might indicate a gap in reporting? But the risk lens says "quarterly_gaps present (unverifiable trend)". The pack might have missing data for some quarters. The quarterly array includes entries for all periods from 2024-12-31 to 2026-03-31. But the entry for 2024-12-31 is just {"period": "2024-12-31"} without any financials. That could be considered a gap in the sense that data is missing for that quarter? However, the annual data covers full year 2024, so quarterly for Q4 2024 might just be incomplete in this extract. The instruction: "quarterly_gaps present" might mean missing quarters in the series, making trend unverifiable. We have: 2026-Q1, 2025-Q4, Q3, Q2, Q1, then 2024-Q4 with no data. But the sequence is still continuous; the data for Q4 2024 is simply not in the pack. But the pack might have omitted it, but the period exists. I think "quarterly_gaps" refers to actual missing quarters in the timeline, like skipping from Q3 to Q1. Here the periods are sequentially listed, no gap. Even though Q4 2024 has no numbers, it's still a listed period; we don't know if it was reported or not. The indicator "largest_gap_3m_pct" in indicators: 23.0216, which is a price gap, not a data gap. So I think no quarterly gaps in the financials. 6. dividend cut: We need evidence of a dividend cut. corporate_actions.history shows a "Cash Dividends" with details "49% cash dividends (49 fils per share)" for year 2026, ex_date 2026-05-01. fundamentals.dividend_yield = 41.1765. fundamentals.payout_ratio = 48.55. There is no historical dividend data to compare. Without a prior dividend, can't determine a cut. So likely no break. Thus, 0 breaks. According to the rule, 0 breaks -> "BUY is a legitimate risk-lens output when the balance sheet is clean and cash conversion strong". So stance should be BUY. But we must also consider confidence and target. Confidence bands: 90-100 = multiple independent cited figures align AND a dated catalyst inside the horizon; 70-89 = several aligned cited figures, no dated catalyst; 50-69 = clear evidence with real conflicts; 30-49 = mixed or one-sided evidence; 10-29 = thin, stale, or gap-ridden evidence — output HOLD below 40. We need to assign confidence. We have a clean balance sheet, high cash, no debt, strong OCF/NI. But what about catalysts inside the horizon? The horizon ends 2026-08-17. There is no specific dated catalyst in the pack that falls between 2026-07-20 and 2026-08-17. Recent events: Q1 2026 results already released on 2026-05-12. Next results would be Q2 2026, but filing dates: the last results filing dates listed: 2026-05-12, then 2026-03-09, etc. The next likely would be around August 2026 for Q2? But not specified. No catalyst mentioned. So no dated catalyst inside horizon. So confidence likely 70-89 if several aligned cited figures. We have multiple positives: strong cash generation, no debt, high dividend yield, low PE, high ROE, etc. But there are some conflicts? The stock has had a negative recent performance: ret_1m_pct -11.28%, ret_3m_pct -9.32%, but 12m up 90.9%. Technicals are weak: RSI 34.8, near oversold; price below 50 and 200 MA; tv_recommend_all -0.49. However, for a risk lens focusing on capital preservation, the balance sheet strength might outweigh technicals. But confidence could be 70-89 due to aligned fundamentals but no near-term catalyst. However, we might argue there is a dated catalyst: the Q2 results might be expected, but no date. So no. We also need to produce a target for the 4-week horizon. The instruction says: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." Since no analyst target, we must derive from pack. With no specific catalyst, a target might be based on mean reversion or something. But the pack gives no explicit target derivation method. We could set target to null if we can't derive. Or we could use the dividend yield or something? The risk lens doesn't typically give a target; the output expects {"target":<num_or_null>}. I'll set to null. Now, we must output ONLY a JSON object with keys: citations, point, risk, stance, confidence, target. citations must be a list of objects with field and value. We need at least 2 citations for non-HOLD stance. We can cite figures that support the BUY: e.g., ocf_to_ni=1.89, debt_to_equity=0.0, advv_30d_aed_m=3.06, etc. Let's craft the JSON. The "point" should be a one-sentence summary citing a figure. "risk" is a one line. stance is "BUY". confidence: I'll assign 75, since several aligned cited figures (strong balance sheet, no debt, high cash conversion) but no dated catalyst. However, we must ensure confidence isn't below 40, it's fine. citations could be: - fundamentals.debt_to_equity: 0.0, showing no leverage. - financial_statements.derived.ocf_to_ni: 1.89, indicating strong cash conversion. - liquidity.advv_30d_aed_m: 3.0638, indicating ample liquidity, no exit risk. - fundamentals.current_ratio: 12.4625, indicating strong liquidity. We need at least 2. I'll pick 3. Now, output JSON. Ensure order: citations, point, risk, stance, confidence, target. I'll write: { "citations": [ {"field": "financial_statements.derived.ocf_to_ni", "value": 1.89}, {"field": "fundamentals.debt_to_equity", "value": 0.0}, {"field": "liquidity.advv_30d_aed_m", "value": 3.0638} ], "point": "Amlak's risk profile is clean with an OCF/NI ratio of 1.89, zero debt, and ADVV of AED 3.06M, confirming strong liquidity and cash generation.", "risk": "No credit or liquidity red flags; fundamentals support capital preservation over the 4-week horizon.", "stance": "BUY", "confidence": 75, "target": null } Double-check: The rules say "0 breaks -> your stance follows the evidence like any analyst (BUY is a legitimate risk-lens output when the balance sheet is clean and cash conversion strong)". So BUY is correct. Confidence 75 is within 70-89 for several aligned cited figures, no dated catalyst. All good.

We are the MACRO-LIQUIDITY lens. The peg and Fed rate are identical for all 61 DFM names, so they cannot by themselves justify a stance. We need to find differentiating name-level figures that make AMLAK more or less exposed to the macro backdrop than the market. We'll weigh macro.fed_funds_rate, macro.vix, macro.yield_curve_2s10s_pct for the backdrop, and then cite AMLAK's own fundamentals.debt_to_equity (rate sensitivity), tv_technicals.beta_1y, liquidity.advv_30d_aed_m (flow sensitivity), and sector/peer percentiles. Also weigh uae_macro_news where present. We are to reason ONLY over this evidence pack and output a JSON with stance (BUY/HOLD/SELL) covering ONLY the 4-week horizon ending 2026-08-17. Non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market. We need at least 2 citations for non-HOLD. Let's extract relevant data: Macro backdrop: - fed_funds_rate: 3.63 (as of 2026-06-01), US 2y yield 4.16%, 10y 4.57%, yield curve 2s10s 0.37% (slightly steep but still relatively flat? Actually 0.37% is positive, not inverted, but moderate). VIX 16.73 (moderate). - UAE macro news: Several, including "UAE private-sector Emiratization surpasses 190,000...", "Jaywan Debuts As UAE's First National Payment Scheme", "Houthis declare naval embargo against Saudi Arabia" (geopolitical risk), etc. The Houthi naval embargo might increase regional tension, could impact UAE sentiment? But it's directed at Saudi Arabia; UAE might be indirectly affected. However, we are to weigh where present. Differentiating name-level figures for AMLAK: - fundamentals.debt_to_equity: 0.0. That's very low; no debt. So extremely low rate sensitivity. Typically, financial companies might be sensitive to interest rates, but with no debt, rising rates might not hurt them via debt servicing. In fact, as a finance company, higher rates might increase net interest margins? But we don't have NIM data. However, debt_to_equity 0.0 means minimal financial leverage, so less vulnerable to rate hikes. But the current macro backdrop has Fed rate at 3.63, relatively moderate. Since debt is zero, the company is less exposed to rising funding costs. - tv_technicals.beta_1y: 0.5589. A beta below 1 indicates lower systematic risk relative to the market. So in a macro downturn, it might fall less. Currently, the market (DFMGI) is down -5.96% over 1 month, -1.19% over 3 months. With beta 0.56, AMLAK should be less sensitive to market moves, implying some defensiveness. - liquidity.advv_30d_aed_m: 3.0638 million AED. That's relatively low liquidity. Illiquid stocks can be more volatile and subject to sharp moves if flows change. In a risk-off macro environment, low liquidity is a negative. - peer_context: sector Financial Services. pe_percentile 4 (very low PE, its PE_ttm is 1.18 vs median 11.32), div_yield_percentile 100 (very high dividend yield 41.18% vs median 4.55%). These are value characteristics. In a macro stress scenario, high dividend yield might be attractive, but it's also possibly a sign of distress if yield is unsustainable. However, payout ratio is 48.55%, which is moderate. Still, the high yield could attract income investors in a low-rate environment. Other technicals: rsi14 34.81 near oversold (30), price down -11.28% 1m, -9.32% 3m, -30.99% max drawdown 1y. So it's been weak. The stock is in Financial Services, which is a sector that could be sensitive to macro, but its zero debt and low beta suggest it might be less correlated. Now, macro liquidity: The Fed rate at 3.63% is moderate, not extremely high, and the yield curve is slightly positive (0.37%). VIX 16.73 suggests moderate volatility. The UAE macro news: the Houthi embargo could escalate regional tensions, which might lead to risk-off sentiment, but the UAE itself is stable. The positive news on Emiratization and Jaywan could support domestic economic activity. Overall, macro backdrop is not extremely negative, but there are risks. For the 4-week horizon: we need a stance. We are the macro-liquidity lens, so we consider how AMLAK will perform relative to the market based on macro exposure. Since debt_to_equity is 0.0, it has no rate sensitivity, which is a positive in a moderately rising rate environment (though rates might be stable or falling? The pack doesn't give future rate expectations, but current rate is 3.63). Low beta (0.56) means it should be less volatile than the market; if the market is weak due to macro concerns, AMLAK might outperform on a relative basis, but absolute returns might still be negative. Low liquidity (advv 3.06M AED) could make it susceptible to price swings if selling pressure emerges. Given the recent price declines and RSI near oversold, it might be due for a bounce if macro stabilizes. But the macro lens primarily looks at exposure to macro factors. Since it's less exposed (zero debt, low beta), we might consider it a relative safe haven, but absolute performance might still be poor. For a 4-week horizon, we need a stance: BUY, HOLD, or SELL. Since the stock has fallen a lot, is it oversold? The macro lens doesn't typically recommend BUY just because it's oversold; we need to see if macro factors favor it. With moderate macro and low exposure, perhaps HOLD is appropriate. But a non-HOLD stance requires citing at least 2 differentiating figures that make it more or less exposed. Could we argue BUY because it's less exposed to macro headwinds? But the macro headwinds aren't extreme; VIX 16.73, curve slightly positive. There's no clear macro catalyst within the horizon. The Houthi embargo news dated today (2026-07-20) might cause market jitters, but AMLAK's low beta might cushion it. Could we argue SELL? Low liquidity might amplify downside if macro worsens, but debt is zero. So conflicting. Given that, a HOLD stance might be most appropriate. But the instructions: "A non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market." So if we go HOLD, we don't have to cite those? It says "non-HOLD stances need at least 2" citations. So HOLD is fine without those differentiating figures, but we might still want to cite some figures to support the point. However, the lens is to justify the stance based on macro exposure. Since the peg and Fed rate are identical, we need to find something. But HOLD might be best given mixed signals. Let's check confidence: "90-100 = multiple independent cited figures align AND a dated catalyst sits inside the horizon; 70-89 = several aligned cited figures, no dated catalyst; 50-69 = clear evidence with real conflicts; 30-49 = mixed or one-sided evidence; 10-29 = thin, stale, or gap-ridden evidence — output HOLD below 40." So if we output HOLD, confidence can be below 40, but not necessarily. We can have a HOLD with confidence in any range? It says "output HOLD below 40" meaning if confidence is below 40, stance must be HOLD. But we can output HOLD with higher confidence too. So we need to assess confidence. Are there any dated catalyst inside the horizon? The horizon ends 2026-08-17. There are no earnings results due? The last results filing was Q1 2026 on 2026-05-12. Next quarterly results would likely be Q2 2026, but we don't have a filing date. The filing dates list includes many, but the next one isn't specified. So no dated catalyst within the horizon. So confidence cannot be 90-100. Could be 70-89 if several aligned cited figures, but we need alignment. What would align? For macro lens, we look at macro sensitivity figures. Debt_to_equity 0.0 and beta 0.5589 both suggest low macro sensitivity, which could be aligned for a defensive stance. But the market is down, and AMLAK is down more? Check relative strength: rel_strength_3m_vs_dfmgi_pct -14.5%, so it's underperforming the market significantly over 3 months. That suggests despite low beta, it's fallen more. That could be due to idiosyncratic factors (maybe profit-taking after huge rise? ret_12m_pct +90.9% so still up a lot but down from high). So the low beta didn't protect it recently. That conflict might reduce confidence. The recommendation: The macro lens should consider that with zero debt and low beta, the stock should be less macro-sensitive, but recent performance shows high volatility (realized_vol_annual_pct 61.49%) and underperformance. Low liquidity could exacerbate moves. Overall, the macro backdrop is not dire, but the stock is in a downtrend. For the next 4 weeks, with no catalyst, it might continue to drift. So HOLD is appropriate. We need to output point and risk. point: one sentence citing a figure. risk: one line. stance: HOLD. confidence: we need to assign. Evidence is mixed: zero debt favors stability, but low liquidity and high recent vol are negatives. The macro backdrop is moderate, with some geopolitical risk. So evidence is conflicted, so confidence in the 50-69 range? "Clear evidence with real conflicts" might be 50-69. We'll pick 55. Citations: we need to cite at least two fields for non-HOLD? Since HOLD is fine without, but we can still include citations for our reasoning. We'll include a couple: fundamentals.debt_to_equity 0.0 and tv_technicals.beta_1y 0.5589, maybe also liquidity.advv_30d_aed_m 3.0638. We'll output these as evidence of low macro sensitivity but note illiquidity risk. Point: "AMLAK exhibits zero debt (debt_to_equity 0.0) and a low 1-year beta of 0.5589, suggesting muted sensitivity to the moderate macro backdrop (Fed 3.63%, VIX 16.73); however, thin liquidity (ADV 3.06M AED) and recent underperformance warrant a neutral stance." Risk: "Geopolitical tensions from the Houthi naval embargo could spike risk premiums and pressure DFM, with low liquidity amplifying downside." target: We don't have a basis for a target within the 4-week horizon, so set to null. Confidence: 55. Now, output JSON with keys in order: citations, point, risk, stance, confidence, target. Make sure citations use dotted paths exactly. For debt_to_equity: field "fundamentals.debt_to_equity", value 0.0. For beta: "tv_technicals.beta_1y", value 0.5589. For liquidity: "liquidity.advv_30d_aed_m", value 3.0638. But we only need at least 2 for non-HOLD, but we are HOLD, so it's okay. We'll include two to support point. The point should be one sentence. The risk one line. Thus, final JSON.

We are asked to output a JSON object for SECTOR specialist lens on AMLAK. We must reason over the evidence pack, cite figures, and provide stance for 4-week horizon ending 2026-08-17. Today is 2026-07-20. The stance must be BUY/HOLD/SELL, with confidence, point, risk, and target (if any) derived from pack evidence. First, understand the company: Amlak Finance PJSC, Financial Services sector. The pack has fundamentals, financial statements, recent disclosures, news, macro, sector news, etc. From the SECTOR specialist lens: we focus on business economics, growth, margins, leverage, dividend durability, grounded in multi-year financial statement trends, sector news. Let's examine key figures: - Spot price: 1.18 AED. - Fundamentals: PE TTM 1.1791, PB 0.567, PS 0.625, ROE 88.9%, ROA 66.8%, net margin 64.19%, rev growth yoy 1413%, EPS growth 3676%, debt/equity 0, current ratio 12.46, dividend yield 41.18%, payout ratio 48.55%. Market cap 1.785B AED. - Financial statements: annual data for 2025: revenue 2993.9M, net income 1470.4M, OCF 2782.5M, FCF 2782.2M, cash 2848.7M, equity 3121.5M, total assets 3416.9M, net margin 49.1%. Compare to 2024: revenue 104.2M, net income 12.5M, net margin 12%. So huge jump in 2025. 2023: revenue 209.6M, net income 259.3M (but net margin 123.7%? That is odd, but maybe due to one-off items). 2022: revenue 108.5M, net income 476.1M, net margin 438.8% - also odd. So historically, revenue was small, net income volatile. 2025 saw massive revenue and income surge. Quarterly: Q1 2026: revenue 54M, net income 51.7M, margin 95.7%. Revenue yoy 67.2% (compared to Q1 2025: 32.3M). Q4 2025: revenue 808.8M, net income -481M (loss). Q3 2025: revenue 2162.7M, net income 1932.8M. So revenue is lumpy, with huge Q3 2025, loss in Q4 2025, smaller Q1 2026. The annual 2025 total revenue 2993.9M = sum of quarters? Q1 2025: 32.3, Q2: 52.4, Q3: 2162.7, Q4: 808.8 = 3056.2, slightly different but close. Net income annual 1470.4 = -481 + 1932.8 -0.9 +27.6 = 1478.5, close. So the huge revenue in 2025 was driven by Q3 and Q4. It might be from sale of Egyptian subsidiary, as per news: "Mlak Finance Exits Egypt With EGP 400 Million Sale" dated 2025-10-27. That sale likely contributed big one-off gains. Also, total income for 2025 was 3.12B according to news headline. So revenue is likely total income including gains. The recent Q1 2026 shows normalized lower revenue (54M) but still high net margin (95.7%) and yoy growth 67.2%. However, compared to 2024 revenue (104M annual), Q1 2026 revenue 54M is already more than half of 2024 annual revenue, so there is some growth. Trends: Revenue CAGR 2y (2023-2025): derived rev_cagr_2y_pct: 277.9% (huge, but driven by one-off). NI CAGR 2y: 138.1%. So multi-year growth is extremely high but not sustainable. Looking at the sector, other financial services in UAE are doing well: sector news shows Bank of Sharjah net profit up 39%, Revolut getting crypto license, etc. But Amlak seems to be a special situation, not a typical bank. It had debt restructuring, early settlement of financing facilities in 2025, and now seems to have a clean balance sheet: debt/equity 0, cash nearly matches total assets? Actually total assets 3416.9M, cash 2848.7M, so mostly cash. Equity 3121.5M, so very little liabilities. Debt is 0. So very strong balance sheet. Dividend yield 41.18%? That seems based on a dividend of 49 fils per share (0.49 AED) on a price of 1.18, yield = 0.49/1.18 = 41.5%, matches. Payout ratio 48.55%, so dividend is well covered by earnings. The ex-date was 2026-05-01, so the dividend has been paid. So the high dividend yield is realized? Actually, price dropped after ex-date? Not sure. But the dividend yield figure is based on trailing dividend and current price, so it's high. Margins: Net margin TTM 64.19%, but that includes the one-off items. Looking at quarterly: Q1 2026 net margin 95.7% (high, but revenue low? Net income 51.7M on revenue 54M, seems almost 100% margin, maybe some cost efficiencies). Q4 2025: -59.5% (loss). Q3 2025: 89.4%. So the margins are volatile but generally high when there are gains. Operating margin 69.73% TTM. Earnings quality: OCF to NI is 1.89, so cash flow backs earnings. FCF margin 92.9% (derived). So strong cash generation. Sector context: peer median PE 11.32, Amlak PE 1.18, which is extremely low. PB 0.567 vs median 1.35. Div yield 41% vs median 4.55%. So appears deeply undervalued on a multiples basis, but that may be because the market recognizes the one-off nature of 2025 earnings. The company is basically a shell with cash and some ongoing operations. Now for the 4-week horizon: any catalysts? The horizon ends 2026-08-17. Q2 2026 results? Usually, results are filed around 45 days after quarter end. Q2 2026 ended June 30, so results likely in August. Looking at past results filing dates: 2025-08-12 for Q2 2025 results. So Q2 2026 results might come around August 12, 2026, which is within the horizon. The catalysts show last_results_filing date 2026-05-12 for Q1 2026. So next filing likely mid-August. That could be a catalyst. Also, recent disclosures: many board meetings, BOD decisions, etc. No specific news of new deals. Sector news: positive outlook for UAE financials, but specific to Amlak, not much. There is a recent news (2026-05-12) about Q1 profit of 52M, which is a normalized profit. If Q2 shows similar or better, it could boost confidence. But we don't have any estimate or consensus. So the catalyst is potential Q2 earnings release, but no specific date confirmed. We can note that historically results were released around August 12. That is just before horizon end (Aug 17). So it's a potential catalyst. But not a definite dated catalyst; we only know last year's date. So confidence may not be 90-100 unless we see a clear dated catalyst. Here, we have a possible catalyst, but no exact date. So confidence likely 70-89 if other factors align. From a sector specialist view, we need to consider the sustainability of the business model. Amlak appears to have transformed after exiting Egypt and settling debts. Now it's a cash-rich company with a small operating finance business. The Q1 2026 revenue of 54M is up 67% yoy, but down sharply from the Q3-Q4 2025 spikes. So what is the normalized earnings power? If we annualize Q1 2026 net income: 51.7M * 4 = 206.8M. Market cap 1785M, that gives a PE of 8.6, which is still below sector median of 11.3. But the company also has a huge cash pile: cash 2848.7M, market cap 1785.5M, so it's trading below net cash? Actually, market cap 1.785B AED, cash 2.849B AED, so market cap < cash. That is extremely cheap. But is the cash distributable? The company paid a large dividend (49% of capital? 49 fils per share, shares outstanding? Market cap / share price = 1.785B / 1.18 = 1.513B shares? Actually, float shares 825M, but total shares? Market cap = share price * outstanding shares. 1.18 * shares = 1.785B, shares = 1.513B. The dividend of 0.49 per share would total 0.49 * 1.513B = 741M AED. That's a large payout from its cash. The payout ratio was 48.55% of earnings, but earnings in 2025 were 1.47B, so dividend 714M approximately. So the company can sustain high dividends if it liquidates. But the balance sheet shows equity 3.12B, cash 2.85B, so most equity is cash. So the company is effectively a cash box. The operating business might be small. The question is: will the market re-rate this stock? Over the 4-week horizon, if Q2 results show continued profitability and perhaps another large cash distribution or buyback, the stock could rise. But the technicals are weak: price is down 11.3% in 1 month, 9.3% in 3 months, RSI 34.8 (approaching oversold), -8.5% vs MA200, MA50 below MA200? MA50 1.3196, MA200 1.2899, current 1.18, so below both. TV recommend all -0.49, strongly negative. So momentum is negative. However, the deep value and potential catalyst of Q2 results might turn it around. But as a SECTOR specialist, we focus on fundamentals and sector trends. The sector is doing well, but Amlak is not a typical sector play; it's a special situation. Its fundamentals are distorted by one-off items. For a 4-week horizon, technicals might dominate. But our mandate is to ground in multi-year financial trends and sector news. Multi-year trends show a company that has resolved legacy issues and is now clean. The revenue trajectory: after years of sub-150M revenue, 2025 spiked to 3B, but that includes one-off gains. The normalized revenue run rate might be around 200M+ (Q1 2026 54M, so annual ~216M). Net income could be 200M+ if margins stay high. That's enough to justify a higher valuation than current market cap, considering cash. Peer median PE is 11.3, so if we apply that to normalized earnings of say 200M, market cap would be 2.26B, which is above current 1.785B, implying upside to 2.26/1.785 * 1.18 = ~1.49 AED. But that is a long-term view; for 4 weeks, we need a shorter target. We need a target derived from pack evidence for the 4-week horizon. We could look at technical support/resistance. The low 52w is 1.15, high 2.01. Price is near the low. Could bounce. But no clear catalyst within 4 weeks to drive to a specific target. The potential Q2 results could be a positive, but if they disappoint, could go lower. So a target may be uncertain. We could set target to a mean-reversion toward the MA200 (1.29) or MA50 (1.32). Given the oversold condition, a bounce could happen. But as per instructions, if we output a target, derive it from evidence. We could use the peer median PB: 1.35, applied to book value per share. Book value equity 3.1215B, shares 1.513B, BVS = 2.063. Median PB 1.35 gives target 2.78, but that seems unrealistic in 4 weeks. More reasonable: if the company announces a special dividend or buyback, but no such news. So maybe we should not set a target, or set it conservatively based on potential mean reversion to MA200 (1.29), but that's technical, not our lens. Our lens is sector/fundamental. So maybe we can derive a target based on normalized PE. Use normalized EPS estimate for 2026? We don't have analyst estimates. We can roughly annualize Q1 EPS. Q1 net income 51.7M, shares 1513M? Wait, market cap 1785M, price 1.18, so shares = 1785/1.18 = 1512.7M. EPS Q1 = 51.7/1512.7 = 0.0342. Annualized: 0.1368. Apply sector median PE 11.32, target price = 0.1368 * 11.32 = 1.548. That's a potential target. But is it justifiable in 4 weeks? If Q2 results confirm this run-rate, the stock might rerate towards that. But Q2 results may come out near the end of the horizon, so the impact might be limited. Confidence in hitting that target in 4 weeks is low. So maybe HOLD with a target of 1.55? But we need confidence band. The evidence is mixed: strong fundamentals (clean balance sheet, high cash, low PE) but weak price momentum. Sector trends positive. Possible catalyst. Conflicts: the huge dividend yield but that was paid, so no further income until next year. The Q1 results were already released and didn't boost the stock; it fell further. So the market might be skeptical. That suggests HOLD. But let's check the stance decision: guidelines say output HOLD below 40 confidence. If our confidence is low, we must output HOLD. If we have enough evidence for BUY, we need confidence >= 40. Can we make a BUY case? As a sector specialist, we see a company with excellent margins, no debt, high cash, and trading below net cash. That's a strong fundamental case. But over 4 weeks, the negative technicals might persist. We need to weigh sector news: UAE financials are doing well, Bank of Sharjah up, etc. But Amlak is not a bank; it's a finance company. No direct sector news on non-bank financials. The recent news "Amlak Finance posts AED52 million in net profit for Q1 2026" was on May 12, and since then the stock has dropped (price 1.18 vs maybe higher then? ret_1m -11.28%, so it was around 1.33 a month ago). So the positive earnings didn't help. The next catalyst is Q2 results, bu

We are asked to output a JSON object with keys: citations, point, risk, stance, confidence, target. The lens is TECHNICAL: trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure (indicators), rel-strength vs DFMGI; if corporate_actions.upcoming_ex_date is present, treat the ex-date drop as mechanical, not a signal. We must reason over the pack evidence, citing exact figures. Today is 2026-07-20, horizon ends 2026-08-17 (4 weeks). The technical lens focus: trend, momentum, volatility, drawdown, relative strength. Also, there's a corporate action: ex-date 2026-05-01, which is already past, so no upcoming ex-date drop to treat as mechanical. So no adjustment needed. First, extract key technical figures from the pack: - Spot price: 1.18 - MA50: 1.3196, MA200: 1.2899 -> MA50 is above MA200 (1.3196 > 1.2899) so golden cross? Actually, MA50 > MA200 is bullish. But price vs MA200: pct_vs_ma200 = -8.5167, meaning price is below MA200. So price < MA200 < MA50? Actually, spot 1.18, MA200 1.2899, MA50 1.3196. So price below both, and MA50 above MA200. That suggests a recent downtrend after being above. - RSI14: 34.8141, near oversold (30), but not yet. - Momentum: ret_1m_pct = -11.2782, ret_3m_pct = -9.3198, ret_12m_pct = +90.9056. So short-term negative, long-term positive. - Relative strength vs DFMGI: rel_strength_3m_vs_dfmgi_pct = -14.5019, underperforming the index. - Vol: realized_vol_annual_pct = 61.4909, high. - max_drawdown_1y_pct = -30.9942, significant. - pct_off_20d_high = -10.6061, near 20-day high? off by 10.6%. - ATR14_pct_of_price = 3.3898%, moderate daily range. - largest_gap_3m_pct = 23.0216, large gap (likely due to dividend ex-date? But ex-date was 2026-05-01, gap could be from that mechanical drop. We treat ex-date drop as mechanical, so we might ignore that gap as a signal. But the gap is a fact in technicals; however, we are to treat it as mechanical, not a signal. So we shouldn't overweigh it. - ADX: 31.7242, indicating a trend (above 25), but direction? - CCI20: -144.7259, oversold. - Stoch K: 18.254, oversold. - Williams %R: -78.5714, oversold. - tv_recommend_all: -0.4909, which is bearish. tv_recommend_ma: -0.8, strongly bearish on moving averages. - beta_1y: 0.5589, low beta. Price action: stock fell from 2.01 (52w high) to 1.15 (52w low), now 1.18, down 41.3% from 52w high (pct_below_52w_high: 41.2935). So it's closer to 52w low. Technical outlook for 4 weeks: The stock is in a downtrend with bearish moving averages (price below both, tv_recommend_ma -0.8). RSI near oversold could suggest a bounce, but momentum is negative. The high volatility and recent losses indicate continued weakness. No clear catalyst in the horizon from technicals. The corporate action (dividend ex-date) already passed, so no mechanical drop expected. There might be support around the 52w low 1.15. But with negative momentum and relative underperformance, the bias is bearish. However, oversold oscillators could spark a short-term bounce, but the trend is down. We need to output stance: BUY, HOLD, or SELL. With technicals this weak, likely SELL or HOLD. But confidence: we need to see if there is dated catalyst inside horizon. The horizon ends 2026-08-17. Looking at catalysts.filings_12mo: 60, but that's past. The next results filing? Not listed. No upcoming known catalyst from the pack. So no dated catalyst. The confidence bands: 70-89 = several aligned cited figures, no dated catalyst. Our case would align several technical figures that point to weakness. So confidence could be 70-89 range if we have multiple aligned signals. Let's pick evidence. Technical evidence: - Price below MA200 (pct_vs_ma200: -8.5167) -> bearish. - Price below MA50 (spot 1.18 vs MA50 1.3196) -> bearish. - MA50 above MA200 but both above price? Actually, MA50 (1.3196) > MA200 (1.2899) > price (1.18)? No, MA200 is 1.2899, price is 1.18, so price is below MA200, and MA200 < MA50. So price is below both, and the shorter MA is above the longer MA (golden cross), but price is below, which might indicate a "bearish alignment" where price broke down through the MAs. Typically, if price < MA200 < MA50, that's bearish. - tv_technicals.tv_recommend_ma = -0.8 (strong sell on moving averages). - tv_recommend_all = -0.4909. - Momentum: negative 1-month and 3-month returns. - Relative strength negative. - RSI below 40, but not extremely oversold. - High volatility. - Large max drawdown. - Oscillators oversold (Stoch, CCI, Williams) could suggest a bounce, but in a downtrend, they can stay oversold. Given these, the technical stance for a 4-week horizon is bearish. But do we have enough to issue a SELL? The pack says: "non-HOLD stances need at least 2 citations." So a SELL might be appropriate if we have strong conviction. But confidence must be based on alignment. Several aligned cited figures: price vs MA200, tv_recommend_ma, rel_strength, ret_1m_pct. So we can cite those. However, there is a conflict: the long-term return is positive (90% 12m) and fundamentals are strong (PE 1.17, ROE 89%, etc.). But we are technical lens only, so we ignore fundamentals for this rating. The instruction: "Weigh fundamentals, analyst consensus ... and technicals as relevant to your lens." But we are the TECHNICAL lens, so we only consider technicals. The other lenses will cover fundamentals. So we should purely base on technicals. Thus, the technical picture is bearish. But do we go SELL? The stock has already corrected significantly, and oversold oscillators might lead to a bounce. The 4-week horizon is short. Could there be a mean-reversion? Without a catalyst, it might continue drifting down or consolidate. Given the negative trend and no catalyst to reverse, a SELL or HOLD. The instruction says: output HOLD below 40 confidence. If we think confidence is 70-89, it's above 40, so we can output SELL. We need to determine confidence. Since there are several aligned figures (price below MA200, negative momentum, tv_recommend_ma strongly bearish, relative weakness), but no dated catalyst in horizon, confidence would be in 70-89. Let's set confidence at 75, for example. But we must not round to defaults; 75 is fine. Point: a single sentence citing a figure. For example: "Price at 1.18 is 8.52% below MA200 (1.2899) with RSI14 at 34.81 and negative 1-month return of -11.28%, signaling sustained weakness." Risk: something like "Potential dead-cat bounce from oversold conditions could trigger short-covering." But that acknowledges the risk of a bounce. Target: For a SELL, we might output a lower target, but derived from pack evidence? With the 4-week horizon, we could estimate based on ATR or support levels. ATR14 is 3.39% of price, so daily ATR ~ 0.04. Over 4 weeks (20 trading days), a potential move might be 20 * 0.04 = 0.80, but that's not standard. Or use support at 52-week low 1.15. That's about 2.5% below current. But with bearish momentum, maybe lower. Actually, price could break 1.15. But we must derive from pack evidence. The pack provides no target guidance. The instruction: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." Since there's no analyst target, we might output null, or if we can derive a simple technical target. For example, using ATR or recent lows. But the instruction says "derive it from pack evidence". I could use the 52-week low as a possible target if we expect a retest. That is in the pack: tv_technicals.low_52w = 1.15. So I could set target as 1.15, suggesting downside to the low. That is evidence-based. Alternatively, null is acceptable if no clear derivation. But let's see: with bearish momentum, a decline to the low is plausible in 4 weeks. I'll set target to 1.15. Citations: we need at least 2 for non-HOLD. We'll pick: - indicators.pct_vs_ma200: -8.5167 - tv_technicals.tv_recommend_ma: -0.8 - indicators.ret_1m_pct: -11.2782 - indicators.rel_strength_3m_vs_dfmgi_pct: -14.5019 I'll list 2 or 3 of these. Let's structure: { "citations": [ {"field": "indicators.pct_vs_ma200", "value": -8.5167}, {"field": "tv_technicals.tv_recommend_ma", "value": -0.8}, {"field": "indicators.ret_1m_pct", "value": -11.2782} ], "point": "Price at 1.18 is 8.52% below MA200 (1.2899) and stochastics are oversold (Stoch K 18.25), confirming a downtrend over the 4-week horizon.", "risk": "A bounce from oversold levels could temporarily lift the stock, but the primary trend remains bearish.", "stance": "SELL", "confidence": 78, "target": 1.15 } But wait: "point" should be one sentence citing a figure. Our point sentence cites multiple, that's fine. I'll include a specific figure. The instruction says: "point: one sentence citing a figure". So at least one figure. I cited two. Okay. Confidence 78 is within 70-89, plausible. Target derived from 52-week low. That's valid. Check: citations fields are dotted paths exactly: "indicators.pct_vs_ma200" value -8.5167, etc. No brackets. Also note: corporate_actions history shows ex-date 2026-05-01, which is already past, so no upcoming ex-date. So we ignore. All good. Now output only JSON.

We are tasked with providing a VALUATION lens rating for AMLAK (Amlak Finance PJSC) over a 4-week horizon ending 2026-08-17, using only the provided evidence pack. We must output a JSON with keys: citations, point, risk, stance, confidence, target. Stance can be BUY, HOLD, SELL. Confidence bands: 90-100 if multiple independent cited figures align AND a dated catalyst inside horizon; 70-89: several aligned cited figures, no dated catalyst; 50-69: clear evidence with real conflicts; 30-49: mixed or one-sided evidence; 10-29: thin, stale, or gap-ridden — and we must output HOLD below 40. We need to cite at least 2 non-HOLD stances. Let's examine pack for valuation multiples, dividend support, analyst consensus, and relevant news/disclosures. Valuation multiples: - fundamentals: pe_ttm = 1.1791, pb = 0.567, ps = 0.625. These are extremely low. Peer context: median_pe_ttm = 11.32, median_pb = 1.35. So AMLAK trades at a fraction of peer medians. pe_percentile = 4, meaning 96% of peers have higher P/E. That suggests deep undervaluation. - earnings: net margin 64.19%, roe 88.91%, roa 66.82%. Revenue growth yoy 1413%, eps growth yoy 3676%. These are extraordinary but note that 2024 annual net income was only 12.5m, so growth from a very low base. However, 2025 annual net income was 1470.4m, huge leap. The quarterly data shows volatility: Q1 2026 net income 51.7m, down from Q3 2025 1932.8m but up from Q1 2025 27.6m. Revenue in Q1 2026 is 54m, much lower than Q3 2025's 2162.7m, but note that the 2025 annual revenue was 2993.9m, with most coming from Q3. The business seems lumpy. Dividend support: fundamentals.dividend_yield = 41.1765%! That's enormous. Payout ratio 48.55%. Corporate actions: cash dividend of 49% (49 fils per share) declared in 2026, ex-date 2026-05-01, payment date 2026-05-15. The yield likely reflects the recent dividend relative to price (spot 1.18 AED). That dividend has already been paid, so ex-dividend. For the 4-week horizon, no upcoming dividend catalyst within the horizon; the next dividend might be declared later. But dividend yield is supportive of value. Analyst consensus: analyst info is all null (n=null, rec=none, target_mean=null). So no analyst consensus to lean on. consensus_signal_drift only has tv_recommend from TradingView? tv_recommend_all = -0.4909, meaning a sell signal. tv_recommend_delta_5d = -0.07, tv_recommend_delta_10d = -0.115, both negative, indicating drift downward. So technical consensus is bearish. Financial health: debt_to_equity 0.0, current_ratio 12.46, very strong balance sheet. Cash 2848.7m, equity 3121.5m, so net cash position. FCF yield? fcf_margin_pct = 92.9% (derived from annual? annual fcf 2782.2 / revenue 2993.9 = 93%). So strong cash generation. OCF to NI = 1.89, good conversion. Technical indicators: RSI 34.81 (oversold territory but not extreme), price vs ma200 -8.52%, ma50 1.3196 > ma200 1.2899, so still above 200-day but below 50-day. ret_1m -11.28%, ret_3m -9.32%, ret_12m +90.91%. So recent pullback. rel_strength_3m_vs_dfmgi -14.5%, underperforming market. High volatility (realized vol 61.5%). ADX 31.7, CCI -144.7 (oversold), Stoch K 18.25, Williams %R -78.57 (oversold). So technically weak and oversold. Catalysts: last results filing on 2026-05-12 for Q1 2026. Next results filing would be Q2 2026, likely in August? The 24-month results filing dates show Q2 2025 was on 2025-08-12, so Q2 2026 might be around 2026-08-12, which falls within the 4-week horizon ending 2026-08-17. That could be a potential catalyst: earnings release. However, the horizon ends 2026-08-17, so if the filing comes on or before that, it's inside. But we don't know the exact date; historically, Q2 was filed on 2025-08-12, so likely 2026-08-12 or later. Since we have no explicit dated catalyst from the pack, we cannot assert it as a definite catalyst. The instructions: "Do not assert a specific dated catalyst... unless it appears in a pack field" - we don't have any filing_context excerpt mentioning an upcoming earnings date. So we cannot rely on a catalyst inside the horizon. Therefore, confidence must be below 90. If we have several aligned cited figures (like multiples, dividend) but no dated catalyst, confidence can be 70-89. Now, valuation lens: At 1.18 AED, with pe_ttm 1.18, pb 0.57, and huge dividend yield, the stock appears deeply undervalued compared to peers. However, the earnings quality: the massive jump in 2025 likely from one-time items or revaluation? The quarterly breakdown shows Q3 2025 had revenue 2162.7m and net income 1932.8m, while other quarters were small. Q1 2026 is back to small. So the low P/E is based on trailing twelve months that include that bumper quarter. As we approach Q2 2026, the TTM earnings will drop off Q3 2025 if not repeated, so P/E will expand dramatically. So the current low P/E is not sustainable; it's a trailing figure that may not repeat. That makes the valuation multiple misleading. The financial statements do not provide details on the nature of the revenue spike. Therefore, a valuation based on TTM P/E might be a value trap. Also, the dividend yield is based on the last dividend paid relative to current price, but the company paid 49% of par (49 fils per share) which is 0.49 AED per share? Actually, spot is 1.18, dividend yield 41.18% implies dividend of about 0.49 AED per share. That's a huge payout. But will it be sustained? The payout ratio is 48.55% of earnings, so if earnings fall back to normal, dividend might not be repeated. The 2025 annual net income was 1470.4m, with 1512.5m shares? market cap 1785m / 1.18 = ~1512.7m shares. So dividend of 0.49 per share totals about 741m, which is roughly 50% of 1470.4m. So the dividend was supported by 2025 earnings. Future dividends depend on future earnings. With Q1 2026 net income only 51.7m, annualizing to ~207m, a 50% payout would be ~0.068 per share, yielding about 5.8%, not 41%. So the dividend support is questionable going forward. The consensus signal drift is negative, technicals are negative, and the market has been selling off. Price is down 11% in one month. Given the valuation lens, there are conflicts: extremely low multiples but based on possibly unsustainable earnings; high dividend yield but unlikely to repeat; strong balance sheet but uncertain earnings. So there is clear evidence with real conflicts (confidence 50-69). However, we must decide stance. As a valuation lens, if we believe the current price does not reflect the true earning power, we might argue it's undervalued. But the 4-week horizon is short, and with negative momentum and no immediate catalyst, the valuation argument may not play out. The policy is: output HOLD below 40 confidence. But here confidence might be in 50-69 range, so we can output BUY or SELL if we reason it. But the instructions say: "Do not assert a specific dated catalyst... unless it appears" so we don't have one. Confidence band: "50-69 = clear evidence with real conflicts". That fits here. So confidence should be between 50 and 69. We need to pick a number. I'd say 60, reflecting moderate conviction due to conflicts. Stance: Given the deep value multiples, but negative drift and questionable sustainability, I'd lean towards HOLD? But valuation lens might still find it attractive. However, the policy for confidence below 40 is HOLD, but above that we can choose. Let's think: The stock is down, RSI oversold, high yield (but ex-dividend). The low P/E is a mirage. So from a valuation perspective, it's not clearly a buy because earnings are volatile and the low multiple is based on peak earnings. The price might be fairly valued if earnings mean-revert. So I'd go with HOLD. But wait, the point should be about valuation multiples vs fair value. The point could be: "AMLAK trades at a P/E of 1.18 vs peer median 11.32, but trailing earnings include a non-recurring spike; fair value may be lower." That's a HOLD. So stance: HOLD. Confidence: I'll choose 60. Target: derive from pack evidence for 4-week horizon. I might not have a target, so null. Check non-HOLD need at least 2 citations. Since HOLD, it's non-HOLD? Actually HOLD is a stance, but the instruction says "non-HOLD stances need at least 2" citations. So HOLD also needs citations? It says: "non-HOLD stances need at least 2" — so BUY/SELL need at least 2, HOLD may have fewer but better to have at least 2 to support. I'll provide citations. citations: need exact dotted paths with values. I'll cite the low P/E and the high dividend yield, and perhaps the negative consensus signal drift. For example: - {"field":"fundamentals.pe_ttm","value":1.1791} - {"field":"peer_context.median_pe_ttm","value":11.32} - {"field":"fundamentals.dividend_yield","value":41.1765} - {"field":"consensus_signal_drift.tv_recommend_all","value":-0.4909} But we need to tie to the point. Point: "AMLAK's P/E of 1.18 is far below peer median 11.32, but trailing earnings are inflated by a one-off 2025 quarter; the 41% dividend yield is likely unsustainable, warranting a hold." That's point. Risk: "Price may decline further if Q2 earnings disappoint or the selloff continues, but strong cash and no debt limit downside." That's risk. Now, derive target: null, as no clear 4-week target from evidence. Confidence: 60. Ensure output order: citations, point, risk, stance, confidence, target. Let's craft final JSON.